Published in Cancer Res on April 19, 2011
Upregulation of MircoRNA-370 induces proliferation in human prostate cancer cells by downregulating the transcription factor FOXO1. PLoS One (2012) 1.30
RNA-binding protein HuD controls insulin translation. Mol Cell (2012) 1.25
FOXO transcription factors: their clinical significance and regulation. Biomed Res Int (2014) 1.14
MicroRNA-196a promotes cervical cancer proliferation through the regulation of FOXO1 and p27Kip1. Br J Cancer (2014) 1.12
Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1. PLoS One (2013) 1.09
Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease. Cancer Res (2015) 1.09
Histone deacetylase 3 suppression increases PH domain and leucine-rich repeat phosphatase (Phlpp)1 expression in chondrocytes to suppress Akt signaling and matrix secretion. J Biol Chem (2013) 1.07
Unraveling the role of FoxOs in bone--insights from mouse models. Bone (2011) 0.96
Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells. J Cell Physiol (2013) 0.93
Genome-wide screening of genes regulated by DNA methylation in colon cancer development. PLoS One (2012) 0.92
A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT signal pathway in prostate cancer. PLoS One (2014) 0.91
Inhibition of FOXO1/3 promotes vascular calcification. Arterioscler Thromb Vasc Biol (2014) 0.90
Caffeic acid phenethyl ester suppresses proliferation and survival of TW2.6 human oral cancer cells via inhibition of Akt signaling. Int J Mol Sci (2013) 0.88
Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance. Br J Cancer (2012) 0.88
RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression. Mol Cancer (2015) 0.87
A specific role for phosphoinositide 3-kinase and AKT in osteoblasts? Front Endocrinol (Lausanne) (2012) 0.86
AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction. EMBO J (2017) 0.84
Knockdown of PRKAR1A, the gene responsible for Carney complex, interferes with differentiation in osteoblastic cells. Mol Endocrinol (2014) 0.84
The Ah receptor regulates growth factor expression in head and neck squamous cell carcinoma cell lines. Mol Carcinog (2013) 0.83
Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness. Cancer Res (2014) 0.83
Runx2 isoform I controls a panel of proinvasive genes driving aggressiveness of papillary thyroid carcinomas. J Clin Endocrinol Metab (2012) 0.83
Genetic polymorphisms of XRCC1 and leukemia risk: a meta-analysis of 19 case-control studies. PLoS One (2013) 0.82
Runx2-Smad signaling impacts the progression of tumor-induced bone disease. Int J Cancer (2014) 0.82
Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies. Neoplasia (2012) 0.82
Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease. Oncogene (2015) 0.81
Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells. Breast Cancer Res (2014) 0.81
Involvement of post-transcriptional regulation of FOXO1 by HuR in 5-FU-induced apoptosis in breast cancer cells. Oncol Lett (2013) 0.81
Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation In Vivo and Human Bladder Cancer Invasion In Vitro by Targeting STAT1/FOXO1 Axis. Cancer Prev Res (Phila) (2016) 0.80
miRNA-135a promotes hepatocellular carcinoma cell migration and invasion by targeting forkhead box O1. Cancer Cell Int (2016) 0.80
MiR-182 Is Associated with Growth, Migration and Invasion in Prostate Cancer via Suppression of FOXO1. J Cancer (2015) 0.80
Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer. Nat Commun (2016) 0.80
Caffeic Acid phenethyl ester is a potential therapeutic agent for oral cancer. Int J Mol Sci (2015) 0.77
Decreased expression of FOXF2 as new predictor of poor prognosis in stage I non-small cell lung cancer. Oncotarget (2016) 0.76
Transcription factor HBP1 is a direct anti-cancer target of transcription factor FOXO1 in invasive oral cancer. Oncotarget (2017) 0.75
Direct binding of MEK1 and MEK2 to AKT induces Foxo1 phosphorylation, cellular migration and metastasis. Sci Rep (2017) 0.75
The P2Y2 nucleotide receptor is an inhibitor of vascular calcification. Atherosclerosis (2016) 0.75
FOXO1 Is Involved in the Effects of Cigarette Smoke Extract on Osteoblastic Differentiation of Cultured Human Periosteum-derived Cells. Int J Med Sci (2015) 0.75
Dicer-dependent pathway contribute to the osteogenesis mediated by regulation of Runx2. Am J Transl Res (2016) 0.75
FOXO1 inhibits the invasion and metastasis of hepatocellular carcinoma by reversing ZEB2-induced epithelial-mesenchymal transition. Oncotarget (2016) 0.75
Prostate cancer: molecular insights into bone metastasis. Nat Rev Urol (2011) 0.75
Fructose-1,6-bisphosphatase inhibits ERK activation and bypasses gemcitabine resistance in pancreatic cancer by blocking IQGAP1-MAPK interaction. Cancer Res (2017) 0.75
MicroRNA-9 promotes the proliferation, migration, and invasion of breast cancer cells via down-regulating FOXO1. Clin Transl Oncol (2017) 0.75
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91
Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell (1997) 16.78
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A (1998) 6.98
Dynamic FoxO transcription factors. J Cell Sci (2007) 6.30
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res (1998) 4.33
Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol Cell Biol (1995) 4.28
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1998) 4.18
A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell (2002) 3.73
Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol (2000) 3.42
CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science (2006) 3.41
Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake. Nat Med (2006) 3.24
Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A (2005) 3.16
Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol (2010) 2.64
FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice. J Clin Invest (2009) 2.46
Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. Nat Neurosci (2006) 2.36
Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res (2005) 2.19
The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol (2005) 2.18
Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem (2001) 2.07
Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev (2006) 2.04
FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res (2006) 2.03
Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol (2004) 1.99
Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene (1998) 1.97
Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem (2004) 1.91
Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene (2009) 1.87
Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res C Embryo Today (2005) 1.84
Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res (2009) 1.80
PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem (2001) 1.72
Transcriptional regulation of osteopontin gene in vivo by PEBP2alphaA/CBFA1 and ETS1 in the skeletal tissues. Oncogene (1998) 1.70
AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol (2003) 1.68
Akt1 in osteoblasts and osteoclasts controls bone remodeling. PLoS One (2007) 1.56
Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem (2007) 1.43
Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase/ERK-dependent and Akt-independent signaling pathway. J Biol Chem (2004) 1.33
A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. Cancer Res (2008) 1.28
Loss of PTEN is associated with progression to androgen independence. Prostate (2006) 1.20
Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells. J Biol Chem (2004) 1.20
MINT, the Msx2 interacting nuclear matrix target, enhances Runx2-dependent activation of the osteocalcin fibroblast growth factor response element. J Biol Chem (2004) 1.13
Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem (2001) 1.13
Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Hum Pathol (2007) 1.06
The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol (2003) 1.05
Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res (2001) 1.03
Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin Cancer Res (2009) 1.00
Cyclin D1 promotes anchorage-independent cell survival by inhibiting FOXO-mediated anoikis. Cell Death Differ (2009) 0.96
The Runx transcriptional co-activator, CBFbeta, is essential for invasion of breast cancer cells. Mol Cancer (2010) 0.95
The TIGR Rice Genome Annotation Resource: improvements and new features. Nucleic Acids Res (2006) 8.26
Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology (2005) 3.40
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res (2002) 3.26
Evidence of focal small-fiber axonal degeneration in complex regional pain syndrome-I (reflex sympathetic dystrophy). Pain (2006) 2.87
Myocardial injury and long-term mortality following moderate to severe carbon monoxide poisoning. JAMA (2006) 2.83
Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol (2010) 2.64
Building bone to reverse osteoporosis and repair fractures. J Clin Invest (2008) 2.40
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A (2008) 2.39
Cystic nephroma and mixed epithelial and stromal tumour of the kidney: opposite ends of the spectrum of the same entity? Eur Urol (2007) 2.33
Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer (2004) 2.22
Immunoglobulin G4-related disease in genitourinary organs: an emerging fibroinflammatory entity often misdiagnosed preoperatively as cancer. Eur Urol (2012) 2.18
Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer. Am J Surg Pathol (2007) 2.17
Immunohistochemical markers in the evaluation of tumors of the urinary bladder: a review. Anal Quant Cytol Histol (2005) 2.14
An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest (2012) 2.13
Feasibility of omitting cortical renorrhaphy during robot-assisted partial nephrectomy: a matched analysis. J Endourol (2015) 2.05
Update on Wnt signaling in bone cell biology and bone disease. Gene (2011) 2.03
Words of wisdom: re: multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects. Eur Urol (2013) 2.00
OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol (2004) 1.99
Removal of oxidative DNA damage via FEN1-dependent long-patch base excision repair in human cell mitochondria. Mol Cell Biol (2008) 1.95
Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem (2004) 1.91
Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysis. Mod Pathol (2006) 1.87
Multimodal imaging guided photothermal therapy using functionalized graphene nanosheets anchored with magnetic nanoparticles. Adv Mater (2012) 1.86
Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res C Embryo Today (2005) 1.84
Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res (2009) 1.80
Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol (2006) 1.80
Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur Urol (2010) 1.79
Sequential posttranslational modifications program FEN1 degradation during cell-cycle progression. Mol Cell (2012) 1.76
Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol (2010) 1.73
Global regulation of gene expression by ArlRS, a two-component signal transduction regulatory system of Staphylococcus aureus. J Bacteriol (2005) 1.72
Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. BJU Int (2009) 1.71
Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci U S A (2013) 1.70
Multiple but dissectible functions of FEN-1 nucleases in nucleic acid processing, genome stability and diseases. Bioessays (2005) 1.69
In utero or ex utero cord blood collection: which is better? Transfusion (2002) 1.64
Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol (2008) 1.64
Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Mol Cell (2012) 1.63
Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin Cancer Res (2005) 1.63
Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets (2009) 1.61
Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol (2010) 1.61
Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Hum Pathol (2008) 1.60
Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors. Blood (2011) 1.60
Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst (2009) 1.59
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol (2011) 1.59
Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc (2009) 1.59
Multivariate statistical differentiation of renal cell carcinomas based on lipidomic analysis by ambient ionization imaging mass spectrometry. Anal Bioanal Chem (2010) 1.58
Lymphoid enhancer factor-1 and beta-catenin inhibit Runx2-dependent transcriptional activation of the osteocalcin promoter. J Biol Chem (2003) 1.57
MST12 regulates infectious growth but not appressorium formation in the rice blast fungus Magnaporthe grisea. Mol Plant Microbe Interact (2002) 1.57
Phase I/II trial of high intensity focused ultrasound for the treatment of previously untreated localized prostate cancer. J Urol (2007) 1.53
The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. Hum Pathol (2007) 1.53
Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. J Biol Chem (2004) 1.53
Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res (2004) 1.53
Refinement of light-responsive transcript lists using rice oligonucleotide arrays: evaluation of gene-redundancy. PLoS One (2008) 1.53
Soft tissue tumors of the urinary bladder, Part I: myofibroblastic proliferations, benign neoplasms, and tumors of uncertain malignant potential. Hum Pathol (2007) 1.52
Extubation failure in pediatric intensive care: a multiple-center study of risk factors and outcomes. Crit Care Med (2003) 1.52
Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res (2005) 1.51
Original Gleason system versus 2005 ISUP modified Gleason system: the importance of indicating which system is used in the patient's pathology and clinical reports. Eur Urol (2010) 1.51
Cholesterol sulfate imaging in human prostate cancer tissue by desorption electrospray ionization mass spectrometry. Anal Chem (2010) 1.48
Incidence, histology and management of intraluminal thrombus at post-chemotherapy retroperitoneal lymph node dissection. J Urol (2013) 1.48
Plasmacytoid urothelial carcinoma of the bladder. Hum Pathol (2009) 1.46
Role of molecular markers in diagnosis and prognosis of renal cell carcinoma. Anal Quant Cytol Histol (2007) 1.45
Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer (2004) 1.45
Side population cells isolated from porcine dental pulp tissue with self-renewal and multipotency for dentinogenesis, chondrogenesis, adipogenesis, and neurogenesis. Stem Cells (2006) 1.43
2009 update on the classification of renal epithelial tumors in adults. Int J Urol (2009) 1.43
Endoloop-assisted laparoscopic partial nephrectomy. J Endourol (2002) 1.42
Evidence supporting the existence of benign teratomas of the postpubertal testis: a clinical, histopathologic, and molecular genetic analysis of 25 cases. Am J Surg Pathol (2013) 1.42
Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner. J Bone Miner Res (2008) 1.42
Two novel fungal virulence genes specifically expressed in appressoria of the rice blast fungus. Plant Cell (2002) 1.41
Chronic disease management for tobacco dependence: a randomized, controlled trial. Arch Intern Med (2011) 1.39
Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high-grade prostatic intraepithelial neoplasia and prostate cancer. Eur Urol (2007) 1.39
Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy. Virchows Arch (2007) 1.39
Large-scale gene discovery in the oomycete Phytophthora infestans reveals likely components of phytopathogenicity shared with true fungi. Mol Plant Microbe Interact (2005) 1.38
Presence of the carcinogen N'-nitrosonornicotine in the urine of some users of oral nicotine replacement therapy products. Cancer Res (2009) 1.38
Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int (2008) 1.36
High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol (2003) 1.35
Nondestructive, histologically compatible tissue imaging by desorption electrospray ionization mass spectrometry. Chembiochem (2011) 1.34
OCT4: A sensitive and specific biomarker for intratubular germ cell neoplasia of the testis. Clin Cancer Res (2004) 1.34
Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res (2008) 1.33
CrossMap: a versatile tool for coordinate conversion between genome assemblies. Bioinformatics (2013) 1.33
Drug delivery with upconversion nanoparticles for multi-functional targeted cancer cell imaging and therapy. Biomaterials (2010) 1.33
A novel stem cell source for vasculogenesis in ischemia: subfraction of side population cells from dental pulp. Stem Cells (2008) 1.32
BRCA1 is a negative modulator of the PRC2 complex. EMBO J (2013) 1.31
Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol (2002) 1.31
Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum Pathol (2006) 1.31
Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. Bone (2011) 1.30
The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. J Clin Pathol (2013) 1.30
Methylation of FEN1 suppresses nearby phosphorylation and facilitates PCNA binding. Nat Chem Biol (2010) 1.29
Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol (2006) 1.29
Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PLoS One (2010) 1.29
p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res (2002) 1.29
Multivariate statistical identification of human bladder carcinomas using ambient ionization imaging mass spectrometry. Chemistry (2011) 1.28
TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol (2013) 1.28
A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. Cancer Res (2008) 1.28
Adult primary paratesticular mesenchymal tumors with emphasis on a case presentation and discussion of spermatic cord leiomyosarcoma. Diagn Pathol (2014) 1.26
Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer (2010) 1.26
Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors. J Cell Biochem (2010) 1.26
Lymphoepithelioma-like carcinoma of the prostate. Hum Pathol (2009) 1.26
Mammalian DNA2 helicase/nuclease cleaves G-quadruplex DNA and is required for telomere integrity. EMBO J (2013) 1.25